Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 June 2018Website:
http://www.kezarlifesciences.comNext earnings report:
14 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:57:38 GMTDividend
Analysts recommendations
Institutional Ownership
KZR Latest News
Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The U.S. Food and Drug Administration has placed a clinical hold on Kezar Life Sciences' trial of experimental drug for lupus, the company said on Friday.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it was informed via teleconference with the U.S. Food and Drug Administration (FDA) that the zetomipzomib Investigational New Drug (IND) application for the treatment of lupus nephritis (LN) has been placed on clinical hold. This action follows Kezar's communication t.
Kezar Life Sciences said on Monday it was stopping enrollment of new patients and dosing of ongoing patients in its mid-stage study for treating a symptom of lupus, following the recommendation of an independent committee after four deaths.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of Directors granted one employee a nonqualified stock option to purchase 80,000 shares of its common stock with an exercise price of $0.71 per share, which is equal to the closing price of Kezar'.
Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.
What type of business is Kezar Life Sciences?
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
What sector is Kezar Life Sciences in?
Kezar Life Sciences is in the Healthcare sector
What industry is Kezar Life Sciences in?
Kezar Life Sciences is in the Biotechnology industry
What country is Kezar Life Sciences from?
Kezar Life Sciences is headquartered in United States
When did Kezar Life Sciences go public?
Kezar Life Sciences initial public offering (IPO) was on 21 June 2018
What is Kezar Life Sciences website?
https://www.kezarlifesciences.com
Is Kezar Life Sciences in the S&P 500?
No, Kezar Life Sciences is not included in the S&P 500 index
Is Kezar Life Sciences in the NASDAQ 100?
No, Kezar Life Sciences is not included in the NASDAQ 100 index
Is Kezar Life Sciences in the Dow Jones?
No, Kezar Life Sciences is not included in the Dow Jones index
When was Kezar Life Sciences the previous earnings report?
No data
When does Kezar Life Sciences earnings report?
The next expected earnings date for Kezar Life Sciences is 14 March 2025